| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IRWDIronwood Pharmaceuticals, Inc. | 735.31M | 4.52 | 821.82 | -20.63% | 8.42% | 14.06% | ||
| TAKTakeda Pharmaceutical Company Limited | 51.59B | 16.33 | 0.49 | 7.45% | 0.75% | 0.46% | 100% | 0.73 |
| RDHLRedHill Biopharma Ltd. | 6.67M | 1.31 | -0.19 | 23.17% | -97.52% | |||
| EVOKEvoke Pharma, Inc. | 18.95M | 11.00 | -3.91 | 97.84% | -36.23% | -155.44% | 0.73 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.81T | 1.73T | 1.77T | 2.1T | 3.29T | 3.2T | 3.57T | 4.03T | 4.26T | 4.58T |
| Revenue Growth % | 0.02% | -0.04% | 0.02% | 0.18% | 0.57% | -0.03% | 0.12% | 0.13% | 0.06% | 0.07% |
| Cost of Goods Sold | 535.4B | 558.75B | 495.92B | 659.69B | 1.09T | 994.31B | 1.11T | 1.24T | 1.43T | 1.58T |
| COGS % of Revenue | 0.3% | 0.32% | 0.28% | 0.31% | 0.33% | 0.31% | 0.31% | 0.31% | 0.34% | 0.34% |
| Gross Profit | 1.27T | 1.17T | 1.27T | 1.44T | 2.2T | 2.2T | 2.46T | 2.78T | 2.83T | 3T |
| Gross Margin % | 0.7% | 0.68% | 0.72% | 0.69% | 0.67% | 0.69% | 0.69% | 0.69% | 0.66% | 0.66% |
| Gross Profit Growth % | 0.01% | -0.08% | 0.09% | 0.13% | 0.53% | 0% | 0.12% | 0.13% | 0.02% | 0.06% |
| Operating Expenses | 1.14T | 1.02T | 1.03T | 1.28T | 2.1T | 1.69T | 2T | 2.29T | 2.62T | 2.66T |
| OpEx % of Revenue | 0.63% | 0.59% | 0.58% | 0.61% | 0.64% | 0.53% | 0.56% | 0.57% | 0.61% | 0.58% |
| Selling, General & Admin | 650.77B | 619.06B | 628.11B | 717.6B | 964.74B | 875.66B | 886.36B | 997.31B | 1.05T | 1.1T |
| SG&A % of Revenue | 0.36% | 0.36% | 0.35% | 0.34% | 0.29% | 0.27% | 0.25% | 0.25% | 0.25% | 0.24% |
| Research & Development | 345.93B | 312.3B | 325.44B | 368.3B | 492.38B | 455.83B | 526.09B | 633.33B | 729.92B | 730.23B |
| R&D % of Revenue | 0.19% | 0.18% | 0.18% | 0.18% | 0.15% | 0.14% | 0.15% | 0.16% | 0.17% | 0.16% |
| Other Operating Expenses | 795.22B | 705.13B | 707.38B | 908.87B | 643.9B | 362.74B | 588.87B | 662.27B | 834.44B | 823.75B |
| Operating Income | 130.83B | 155.87B | 241.79B | 204.97B | 100.41B | 509.27B | 460.84B | 490.5B | 214.07B | 342.59B |
| Operating Margin % | 0.07% | 0.09% | 0.14% | 0.1% | 0.03% | 0.16% | 0.13% | 0.12% | 0.05% | 0.07% |
| Operating Income Growth % | 2.01% | 0.19% | 0.55% | -0.15% | -0.51% | 4.07% | -0.1% | 0.06% | -0.56% | 0.6% |
| EBITDA | 328.21B | 327.29B | 423.92B | 452.66B | 684.06B | 1.07T | 1.04T | 1.15T | 858.54B | 1.1T |
| EBITDA Margin % | 0.18% | 0.19% | 0.24% | 0.22% | 0.21% | 0.33% | 0.29% | 0.29% | 0.2% | 0.24% |
| EBITDA Growth % | 1.49% | -0% | 0.3% | 0.07% | 0.51% | 0.56% | -0.02% | 0.11% | -0.26% | 0.29% |
| D&A (Non-Cash Add-back) | 197.38B | 171.43B | 182.13B | 247.69B | 583.65B | 559.67B | 583.15B | 664.4B | 644.46B | 761.4B |
| EBIT | 152.47B | 150.91B | 227.24B | 175.77B | 88.26B | 424.05B | 600.06B | 619.67B | 499.48B | 449.12B |
| Net Interest Income | -10.29B | -6.97B | -6.78B | -60.96B | -146.65B | -128.65B | -117.67B | -111.19B | -140.46B | -117.67B |
| Interest Income | 21.64B | 12.27B | 39.54B | 6.62B | 27.83B | 1.78B | 4.59B | 5.51B | 11.29B | 19.64B |
| Interest Expense | 31.93B | 23.25B | 31.93B | 48.16B | 165.01B | 130.81B | 122.43B | 116.97B | 153.63B | 137.31B |
| Other Income/Expense | -10.29B | -12.52B | -24.58B | -110.07B | -161.16B | -143.03B | -158.27B | -115.42B | -161.28B | -167.5B |
| Pretax Income | 120.54B | 143.35B | 217.21B | 94.9B | -60.75B | 366.24B | 302.57B | 375.09B | 52.79B | 175.08B |
| Pretax Margin % | 0.07% | 0.08% | 0.12% | 0.05% | -0.02% | 0.11% | 0.08% | 0.09% | 0.01% | 0.04% |
| Income Tax | 37.06B | 27.83B | 30.5B | -14.12B | -105.04B | -9.94B | 72.41B | 58.05B | -91.41B | 66.94B |
| Effective Tax Rate % | 0.67% | 0.8% | 0.86% | 1.15% | -0.73% | 1.03% | 0.76% | 0.85% | 2.73% | 0.62% |
| Net Income | 80.17B | 114.94B | 186.89B | 109.13B | 44.24B | 376B | 230.06B | 317.02B | 144.07B | 107.93B |
| Net Margin % | 0.04% | 0.07% | 0.11% | 0.05% | 0.01% | 0.12% | 0.06% | 0.08% | 0.03% | 0.02% |
| Net Income Growth % | 1.55% | 0.43% | 0.63% | -0.42% | -0.59% | 7.5% | -0.39% | 0.38% | -0.55% | -0.25% |
| Net Income (Continuing) | 83.48B | 115.51B | 186.71B | 135.08B | 44.29B | 376.17B | 230.17B | 317.04B | 144.2B | 108.14B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 62.51B | 54.7B | 19.98B | 4.01B | 4B | 4.14B | 504M | 549M | 741M | 895M |
| EPS (Diluted) | 50.86 | 73.13 | 118.78 | 34.78 | 14.13 | 119.48 | 72.94 | 100.97 | 45.58 | 33.62 |
| EPS Growth % | 2.09% | 0.44% | 0.62% | -0.71% | -0.59% | 7.46% | -0.39% | 0.38% | -0.55% | -0.26% |
| EPS (Basic) | 51.13 | 73.58 | 119.68 | 34.78 | 14.21 | 120.36 | 73.57 | 102.15 | 46.05 | 34.17 |
| Diluted Shares Outstanding | 1.58B | 1.57B | 1.57B | 1.93B | 3.13B | 3.15B | 3.15B | 3.14B | 3.16B | 3.21B |
| Basic Shares Outstanding | 1.57B | 1.56B | 1.56B | 1.92B | 3.11B | 3.12B | 3.13B | 3.1B | 3.13B | 3.21B |
| Dividend Payout Ratio | 1.77% | 1.23% | 0.76% | 1.31% | 6.39% | 0.75% | 1.23% | 0.88% | 1.99% | 2.8% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.37T | 1.26T | 1.08T | 3.05T | 2.47T | 2.71T | 2.59T | 2.4T | 2.56T | 2.52T |
| Cash & Short-Term Investments | 560.03B | 376.14B | 375.17B | 725.37B | 653.44B | 1T | 875B | 553.7B | 472.89B | 405.59B |
| Cash Only | 451.43B | 319.45B | 294.52B | 702.09B | 637.61B | 966.22B | 849.7B | 533.53B | 457.8B | 385.11B |
| Short-Term Investments | 108.6B | 56.68B | 80.65B | 23.28B | 15.82B | 36.6B | 25.3B | 20.17B | 15.09B | 20.48B |
| Accounts Receivable | 430.57B | 444.78B | 428.79B | 749.12B | 784.92B | 812.71B | 724.38B | 681.69B | 697.61B | 725.25B |
| Days Sales Outstanding | 86.95 | 93.73 | 88.4 | 130.38 | 87.05 | 92.76 | 74.08 | 61.78 | 59.72 | 57.78 |
| Inventory | 254.01B | 226.29B | 212.94B | 986.74B | 759.6B | 753.88B | 853.17B | 986.46B | 1.21T | 1.22T |
| Days Inventory Outstanding | 173.17 | 147.82 | 156.73 | 545.96 | 254.42 | 276.74 | 281.35 | 289.42 | 308.49 | 281.18 |
| Other Current Assets | 129.18B | 213.45B | 61.9B | 622.15B | 271.48B | 143.48B | 141.1B | 176.1B | 178.21B | 173B |
| Total Non-Current Assets | 2.45T | 3.1T | 3.03T | 10.82T | 10.35T | 10.2T | 10.58T | 11.56T | 12.55T | 11.73T |
| Property, Plant & Equipment | 551.92B | 530.15B | 536.8B | 1.32T | 1.39T | 1.45T | 1.58T | 1.69T | 1.99T | 1.97T |
| Fixed Asset Turnover | 3.27x | 3.27x | 3.30x | 1.59x | 2.37x | 2.20x | 2.25x | 2.38x | 2.14x | 2.33x |
| Goodwill | 779.32B | 1.02T | 1.03T | 4.16T | 4.01T | 4.03T | 4.41T | 4.79T | 5.41T | 5.32T |
| Intangible Assets | 743.13B | 1.07T | 1.01T | 4.86T | 4.17T | 3.91T | 3.82T | 4.27T | 4.27T | 3.63T |
| Long-Term Investments | 159.56B | 303.05B | 304.38B | 306.9B | 369.45B | 348.35B | 330.13B | 378.86B | 430.61B | 361.93B |
| Other Non-Current Assets | 45.6B | 54.41B | 77.98B | 87.47B | 103.85B | 100.34B | 82.61B | 63.33B | 51.21B | 441.03B |
| Total Assets | 3.82T | 4.36T | 4.11T | 13.87T | 12.82T | 12.91T | 13.18T | 13.96T | 15.11T | 14.25T |
| Asset Turnover | 0.47x | 0.40x | 0.43x | 0.15x | 0.26x | 0.25x | 0.27x | 0.29x | 0.28x | 0.32x |
| Asset Growth % | -0.11% | 0.14% | -0.06% | 2.38% | -0.08% | 0.01% | 0.02% | 0.06% | 0.08% | -0.06% |
| Total Current Liabilities | 857.21B | 1.37T | 737.51B | 2.51T | 2.18T | 1.77T | 2.15T | 2.48T | 2.31T | 2.51T |
| Accounts Payable | 92.07B | 54.88B | 133.71B | 212.35B | 211.63B | 232.1B | 295.93B | 307.45B | 319.95B | 475.54B |
| Days Payables Outstanding | 62.77 | 35.85 | 98.41 | 117.49 | 70.88 | 85.2 | 97.59 | 90.2 | 81.58 | 109.84 |
| Short-Term Debt | 228.46B | 545.03B | 18M | 984.95B | 586.82B | 22.15B | 203.99B | 339.6B | 367.25B | 548.94B |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 0 |
| Other Current Liabilities | 490.18B | 693.49B | 601.66B | 1.35T | 748.39B | 902.44B | 947.51B | 1.03T | 1.45T | 1.48T |
| Current Ratio | 1.60x | 0.92x | 1.46x | 1.21x | 1.13x | 1.53x | 1.21x | 0.97x | 1.11x | 1.01x |
| Quick Ratio | 1.31x | 0.76x | 1.17x | 0.82x | 0.79x | 1.10x | 0.81x | 0.57x | 0.58x | 0.52x |
| Cash Conversion Cycle | 197.35 | 205.71 | 146.72 | 558.84 | 270.58 | 284.3 | 257.84 | 260.99 | 286.63 | 229.12 |
| Total Non-Current Liabilities | 955.67B | 1.04T | 1.35T | 6.2T | 5.92T | 5.96T | 5.35T | 5.12T | 5.52T | 4.81T |
| Long-Term Debt | 539.76B | 599.86B | 985.64B | 4.77T | 4.51T | 4.61T | 4.14T | 4.04T | 4.48T | 3.97T |
| Capital Lease Obligations | 50.62B | 56.7B | 51.02B | 177.27B | 328.38B | 386.23B | 411.36B | 419.73B | 553.43B | 550.9B |
| Deferred Tax Liabilities | 123.47B | 165.16B | 90.72B | 867.06B | 710.15B | 542.85B | 451.51B | 270.62B | 113.78B | 35.15B |
| Other Non-Current Liabilities | 122.53B | 374.92B | 108.5B | 1.11T | 123.55B | 188.35B | 124.8B | 179.93B | 377.98B | 288.62B |
| Total Liabilities | 1.81T | 2.41T | 2.09T | 8.71T | 8.09T | 7.74T | 7.49T | 7.6T | 7.83T | 7.31T |
| Total Debt | 768.22B | 1.14T | 985.66B | 5.75T | 5.46T | 4.64T | 4.81T | 4.86T | 5.46T | 5.07T |
| Net Debt | 316.8B | 825.43B | 691.14B | 5.05T | 4.83T | 3.67T | 3.96T | 4.33T | 5.01T | 4.68T |
| Debt / Equity | 0.38x | 0.59x | 0.49x | 1.11x | 1.16x | 0.90x | 0.85x | 0.77x | 0.75x | 0.73x |
| Debt / EBITDA | 2.34x | 3.50x | 2.33x | 12.70x | 7.99x | 4.34x | 4.61x | 4.21x | 6.36x | 4.59x |
| Net Debt / EBITDA | 0.97x | 2.52x | 1.63x | 11.15x | 7.05x | 3.43x | 3.79x | 3.75x | 5.83x | 4.24x |
| Interest Coverage | 4.10x | 6.70x | 7.57x | 4.26x | 0.61x | 3.89x | 3.76x | 4.19x | 1.39x | 2.49x |
| Total Equity | 2.01T | 1.95T | 2.02T | 5.16T | 4.73T | 5.18T | 5.68T | 6.35T | 7.27T | 6.94T |
| Equity Growth % | -0.09% | -0.03% | 0.04% | 1.56% | -0.08% | 0.1% | 0.1% | 0.12% | 0.14% | -0.05% |
| Book Value per Share | 1275.87 | 1239.98 | 1282.19 | 2670.19 | 1509.22 | 1645.08 | 1801.81 | 2023.95 | 2301.40 | 2160.26 |
| Total Shareholders' Equity | 1.95T | 1.89T | 2T | 5.16T | 4.72T | 5.17T | 5.68T | 6.35T | 7.27T | 6.94T |
| Common Stock | 133.59B | 140.18B | 168.65B | 1.64T | 1.67T | 1.67T | 1.68T | 1.68T | 1.68T | 1.69T |
| Retained Earnings | 1.52T | 1.51T | 1.56T | 1.57T | 1.37T | 1.51T | 1.48T | 1.54T | 1.39T | 1.19T |
| Treasury Stock | -35.97B | -48.73B | -74.37B | -57.14B | -87.46B | -59.55B | -116.01B | -100.32B | -51.26B | -74.81B |
| Accumulated OCI | 327.94B | 291B | -4.79B | 349.88B | 92.56B | 366.11B | 934.17B | 1.51T | 2.51T | 2.35T |
| Minority Interest | 62.51B | 54.7B | 19.98B | 4.01B | 4B | 4.14B | 504M | 549M | 741M | 895M |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 25.49B | 261.36B | 377.85B | 328.48B | 669.75B | 1.01T | 1.12T | 977.16B | 716.34B | 1.06T |
| Operating CF Margin % | 0.01% | 0.15% | 0.21% | 0.16% | 0.2% | 0.32% | 0.31% | 0.24% | 0.17% | 0.23% |
| Operating CF Growth % | -0.86% | 9.25% | 0.45% | -0.13% | 1.04% | 0.51% | 0.11% | -0.13% | -0.27% | 0.48% |
| Net Income | 83.48B | 115.51B | 186.71B | 109.01B | 44.29B | 376.17B | 230.17B | 317.04B | 144.07B | 107.93B |
| Depreciation & Amortization | 197.38B | 222.79B | 182.13B | 272.45B | 583.65B | 559.67B | 583.15B | 664.4B | 728B | 761.4B |
| Stock-Based Compensation | 14.71B | 17.41B | 18.61B | 20.08B | 29.12B | 37.66B | 43.37B | 60.67B | 70.87B | 72.87B |
| Deferred Taxes | 37.06B | 27.83B | 30.5B | -14.12B | -105.04B | -9.94B | 72.41B | 58.05B | -91.41B | 0 |
| Other Non-Cash Items | 22.1B | 25.49B | -53.49B | -134.89B | 23.06B | -228.42B | 95.4B | -97.74B | 120.81B | 167.25B |
| Working Capital Changes | -267.21B | 29.68B | 13.4B | 75.95B | 94.67B | 275.78B | 98.61B | -25.26B | -256B | -52.25B |
| Change in Receivables | 12.37B | -37.31B | -647M | -13.38B | -34.83B | -9.32B | 127.29B | 75.13B | 15.1B | -58.96B |
| Change in Inventory | -6.84B | 3.89B | 13.72B | 58.68B | 137.49B | 25.98B | -46.15B | -79.16B | -115.74B | -34.97B |
| Change in Payables | 17.91B | 42.56B | 6.86B | -16.41B | -29.93B | 210.02B | 75.55B | -53.13B | -9.89B | 0 |
| Cash from Investing | -71.21B | -655.69B | -93.34B | -2.84T | 292.12B | 393.53B | -198.13B | -607.1B | -463.86B | -367.06B |
| Capital Expenditures | -84.86B | -112.03B | -128.26B | -134.11B | -217.71B | -236.47B | -186.04B | -633.69B | -175.42B | -200.79B |
| CapEx % of Revenue | 0.05% | 0.06% | 0.07% | 0.06% | 0.07% | 0.07% | 0.05% | 0.16% | 0.04% | 0.04% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 4.26B | -12.09B | 26.08B | 124.03B | 11.32B | 37.6B | 808M | 6.53B | -251.66B | -166.26B |
| Cash from Financing | -124.84B | 289.9B | -326.23B | 2.95T | -1.01T | -1.09T | -1.07T | -709.15B | -354.42B | -751.42B |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | -141.54B | -141.69B | -141.89B | -142.95B | -282.58B | -283.36B | -283.67B | -279.42B | -287.19B | -302.5B |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -6.88B | -16.72B | -12.44B | -71.14B | -132.8B | -291.39B | -108.59B | -117.73B | -66.42B | -82.75B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -59.37B | 149.34B | 249.59B | 194.37B | 452.04B | 774.46B | 937.07B | 343.47B | 235.61B | 856.39B |
| FCF Margin % | -0.03% | 0.09% | 0.14% | 0.09% | 0.14% | 0.24% | 0.26% | 0.09% | 0.06% | 0.19% |
| FCF Growth % | -1.8% | 3.52% | 0.67% | -0.22% | 1.33% | 0.71% | 0.21% | -0.63% | -0.31% | 2.63% |
| FCF per Share | -37.66 | 95.01 | 158.63 | 100.51 | 144.31 | 246.09 | 297.07 | 109.39 | 74.55 | 266.73 |
| FCF Conversion (FCF/Net Income) | 0.32x | 2.27x | 2.02x | 3.01x | 15.14x | 2.69x | 4.88x | 3.08x | 4.97x | 9.80x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 112.98B |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 3.8% | 5.8% | 9.42% | 3.04% | 0.89% | 7.59% | 4.24% | 5.27% | 2.11% | 1.52% |
| Return on Invested Capital (ROIC) | 4.26% | 4.58% | 6.61% | 2.38% | 0.76% | 4.15% | 3.74% | 3.62% | 1.4% | 2.15% |
| Gross Margin | 70.38% | 67.74% | 71.99% | 68.54% | 66.89% | 68.91% | 68.99% | 69.11% | 66.43% | 65.51% |
| Net Margin | 4.44% | 6.64% | 10.56% | 5.2% | 1.34% | 11.76% | 6.45% | 7.87% | 3.38% | 2.36% |
| Debt / Equity | 0.38x | 0.59x | 0.49x | 1.11x | 1.16x | 0.90x | 0.85x | 0.77x | 0.75x | 0.73x |
| Interest Coverage | 4.10x | 6.70x | 7.57x | 4.26x | 0.61x | 3.89x | 3.76x | 4.19x | 1.39x | 2.49x |
| FCF Conversion | 0.32x | 2.27x | 2.02x | 3.01x | 15.14x | 2.69x | 4.88x | 3.08x | 4.97x | 9.80x |
| Revenue Growth | 1.66% | -4.17% | 2.22% | 18.45% | 56.93% | -2.84% | 11.61% | 12.85% | 5.87% | 7.45% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Gastroenterology | - | 697.9B | 777.8B | 875.68B | 1.09T | 1.22T | 1.36T |
| Gastroenterology Growth | - | - | 11.45% | 12.58% | 24.99% | 11.12% | 11.58% |
| PDT Immunology | - | 394.17B | 420.39B | 506.95B | 678.44B | 818.57B | 1.03T |
| PDT Immunology Growth | - | - | 6.65% | 20.59% | 33.83% | 20.65% | 26.15% |
| Rare Diseases | - | 634.89B | 591.75B | - | 723.44B | 770.7B | 752.82B |
| Rare Diseases Growth | - | - | -6.80% | - | - | 6.53% | -2.32% |
| Neuroscience | - | 438.52B | 417.3B | 482.29B | 637.71B | 627.01B | 565.82B |
| Neuroscience Growth | - | - | -4.84% | 15.58% | 32.22% | -1.68% | -9.76% |
| Oncology | - | 420.96B | 416.51B | 468.73B | 438.74B | 462.36B | 560.43B |
| Oncology Growth | - | - | -1.06% | 12.54% | -6.40% | 5.38% | 21.21% |
| Other Product | - | 704.76B | 574.07B | 624.15B | 454.6B | 368.91B | 257.39B |
| Other Product Growth | - | - | -18.54% | 8.72% | -27.17% | -18.85% | -30.23% |
| Vaccines | - | - | - | - | - | - | 55.41B |
| Vaccines Growth | - | - | - | - | - | - | - |
| Rare Hematology | - | 334.24B | 289.8B | 283.69B | 304.72B | 305.3B | - |
| Rare Hematology Growth | - | - | -13.30% | -2.11% | 7.41% | 0.19% | - |
| Rare Metabolic | - | 170.82B | 162.62B | 172.59B | - | - | - |
| Rare Metabolic Growth | - | - | -4.80% | 6.13% | - | - | - |
| Hereditary Angioedema | - | 129.82B | 139.33B | 153.59B | - | - | - |
| Hereditary Angioedema Growth | - | - | 7.32% | 10.23% | - | - | - |
| Pharmaceutical Products | 2.03T | - | - | - | - | - | - |
| Pharmaceutical Products Growth | - | - | - | - | - | - | - |
| Royalty And Services | 70.95B | - | - | - | - | - | - |
| Royalty And Services Growth | - | - | - | - | - | - | - |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 828.99B | 1.6T | 1.57T | 1.71T | 2.1T | 2.2T | 2.38T |
| UNITED STATES Growth | - | 92.52% | -1.75% | 9.34% | 22.71% | 4.37% | 8.38% |
| Europe And Canada | 405.64B | 645.53B | 666.18B | 739.17B | 842.67B | 966.84B | 1.06T |
| Europe And Canada Growth | - | 59.14% | 3.20% | 10.96% | 14.00% | 14.73% | 9.14% |
| JAPAN | 571.02B | 592.79B | 559.75B | 658.98B | 512.04B | 451.39B | 418.46B |
| JAPAN Growth | - | 3.81% | -5.57% | 17.73% | -22.30% | -11.85% | -7.30% |
| Latin America | 88.11B | 143.46B | 121.64B | 128.47B | 160.38B | 198.1B | 235.85B |
| Latin America Growth | - | 62.81% | -15.21% | 5.61% | 24.84% | 23.52% | 19.06% |
| CHINA | - | - | - | - | - | - | 191.74B |
| CHINA Growth | - | - | - | - | - | - | - |
| Other Countries Not Separately Reported | 38.31B | 71.26B | 68.52B | 68.94B | 95.18B | 117.91B | 128.85B |
| Other Countries Not Separately Reported Growth | - | 85.98% | -3.85% | 0.62% | 38.05% | 23.88% | 9.28% |
| Asia, Excluding Japan And China | - | - | - | - | - | - | 99.39B |
| Asia, Excluding Japan And China Growth | - | - | - | - | - | - | - |
| Asia, Excluding Japan | - | - | - | 196.96B | 225.01B | 261.22B | - |
| Asia, Excluding Japan Growth | - | - | - | - | 14.24% | 16.09% | - |
| Asia | 105.41B | 165.4B | 156.24B | - | - | - | - |
| Asia Growth | - | 56.91% | -5.54% | - | - | - | - |
Takeda Pharmaceutical Company Limited (TAK) has a price-to-earnings (P/E) ratio of 0.5x. This may indicate the stock is undervalued or faces growth challenges.
Takeda Pharmaceutical Company Limited (TAK) reported $4.42T in revenue for fiscal year 2024. This represents a 193% increase from $1.51T in 2011.
Takeda Pharmaceutical Company Limited (TAK) grew revenue by 7.5% over the past year. This is steady growth.
Yes, Takeda Pharmaceutical Company Limited (TAK) is profitable, generating $33.03B in net income for fiscal year 2024 (2.4% net margin).
Yes, Takeda Pharmaceutical Company Limited (TAK) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
Takeda Pharmaceutical Company Limited (TAK) has a return on equity (ROE) of 1.5%. This is below average, suggesting room for improvement.
Takeda Pharmaceutical Company Limited (TAK) generated $977.79B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.